Cargando…
IDF21-0690 Diabetics hospitalized for covid infection under corticosteroid therapy, what is the particularity?
Autores principales: | Yousra, L., Siham, R., Hanane, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Scientific Publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164794/ http://dx.doi.org/10.1016/j.diabres.2022.109391 |
Ejemplares similares
-
Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2021) -
Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2019) -
IDF21-0168 Pathway to Clinical Diabetes Services in COVID-19 Era: What Has Changed and What Are the Implications?
por: Adwubi, E., et al.
Publicado: (2022) -
IDF21-0444 Association Between Prior Antidiabetic Therapy and Outcome in Hospitalized COVID-19 Diabetic Subjects
por: Baidya, A., et al.
Publicado: (2022) -
IDF21-0539 Can the asymptomatic COVID-19 trigger the development of diabetes mellitus?
por: Jashi, L., et al.
Publicado: (2022)